Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?

LUPKYNIS has had a lengthy and ultimately productive development pathway. Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch.

Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet

Aurinia Pharmaceuticals Inc. has strengthened its patent position in the industry and now has more clout as a marketer than just a developer of therapies. Its lead product, LUPKYNIS, an immunosuppressive drug for lupus nephritis, appears to be a highly qualified product to capture a profitable market that offers growth opportunities.

Aurinia Pharmaceuticals Has Strong Upside Potential

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Maury Raycroft - Jefferies Joseph Schwartz - SVB Securities Stacy Ku - Cowen and Company Ed Arce - H.C. Wainwright David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call.

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference

Cytokinetics

FibroGen

Theravance Biopharma

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023

Sotera Health

Many traders are attracted to low-priced stocks because they come with the allure of 2x, 3x or greater short-term gains. For fundamentalists, the challenge is finding such companies that have established businesses, products and customers.

These 2 Healthcare Stocks Have Doubled in 2023

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States' Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia's U.S. Patent No. 10,286,036.

Aurinia Announces PTAB Has Terminated Inter Partes Review

Canadian National Railway Company

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly allowed U.S. Patent Application (No. 17/713,140) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids using eGFR as a method of pharmacodynamically dosing the product in patients with lupus nephritis. The newly allowed application provides patent coverage that supplements Aurinia's existing U.S. Patent No. 10,286,036, which is listed in the Orange Book and claims an FDA-approved method of using LUPKYNIS. The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label. This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037. The Company intends to list this newly allowed patent in the Orange Book once issued.

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

A patent settlement and improved financials sent the stock soaring.

Why Shares of Aurinia Pharmaceuticals Soared This Week

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its business performance. Preliminary unaudited net revenue for the three months and full year ended December 31, 2022 was approximately $28.4 million and $134.0 million. For the three months ended December 31, 2022, preliminary unaudited net revenues included net product revenues of approximately $28.3 million and license and collaboration revenue of approximately $0.1 million. For the full year ended December 31, 2022, preliminary unaudited net revenues included net product revenues of approximately $103.5 million and license and collaboration revenue of approximately $30.5 million. As of December 31, 2022, Aurinia had unaudited cash, cash equivalents and restricted cash and investments of approximately $388.7 million.

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results

Aurinia Pharmaceuticals Inc. recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter.

Aurinia's Patent Dispute Is Over, But Without A Buyout, There's No Upside

Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and counterclaims against each other. Following the settlement announcement, AUPH shares jumped up over 30%, and have since climbed to around $6.75 per share. This settlement removes a significant overhang for the company and AUPH.

Aurinia Pharmaceuticals: Lupkynis Patent Settlement Removes Overhang

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time in San Francisco, CA.

Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

The shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) are soaring today, after the company announced a patent settlement agreement with Sun Pharmaceutical Industries Ltd (SUN) related to its lupus nephritis treatment drug, Lupkynis.

Biotech Stock Blasting Higher After Settlement

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and Sun Pharmaceuticals filing a joint motion to terminate the ongoing Inter Partes Review (IPR) directed at Aurinia's U.S. Patent No. 10,286,036, as well as settlement of the ongoing patent infringement litigation in the United States (U.S.) related to Sun's CEQUA® product. Under the settlement agreement, which is contingent upon the U.S. Patent Trial and Appeal Board approving the joint motion to terminate the IPR, both parties agreed to dismiss their claims and counterclaims against each other and cease bringing any future further action against the other.

Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals

VICTORIA, British Columbia--( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Great Britain marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis

Aurinia has been facing many problems. Potential sales chatter may be a result of its problems.

Aurinia: A Commercial Stage Company With Major Headwinds

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Joseph Schwartz - SVB Securities Ken Cacciatore - Cowen & Company Justin Kim - Oppenheimer & Company Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Maury Raycroft - Jefferies Operator Greetings, and welcome to Aurinia Pharmaceuticals Inc. Third Quarter 2022 Earnings Call.

Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Call Transcript

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH ) stock are down 30% today after the company reported its latest financial results and lowered its forward guidance. AUPH stock is one of the top trending tickers on Stocktwits today following decent financial results not only for the third quarter but also through the first nine months of the year.

Why Is Aurinia Pharmaceuticals (AUPH) Stock Down 30%?

VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2022 FINANCIAL AND OPERATIONAL RESULTS

News for Aurinia Pharmaceuticals Stock (AUPH)